Institutional members access full text with Ovid®

Share this article on:

Third-hand Smoke: Impact on Hemostasis and Thrombogenesis

Karim, Zubair A. PhD*; Alshbool, Fatima Z. PharmD, PhD*; Vemana, Hari Priya BSc*; Adhami, Neema BSc; Dhall, Sandeep PhD; Espinosa, Enma V. P. MD, PhD*; Martins-Green, Manuela PhD; Khasawneh, Fadi T. PhD*

Erratum

In the article that appeared on page 177 of the August 2015 issue, the affiliation for the author Dr. Fatima Z. Alshbool was listed incorrectly. The correct affiliation is the Department of Pharmacology, Loma Linda University, Loma Linda, CA.

Journal of Cardiovascular Pharmacology. 66(6):610, December 2015.

Journal of Cardiovascular Pharmacology: August 2015 - Volume 66 - Issue 2 - p 177–182
doi: 10.1097/FJC.0000000000000260
Original Article

Abstract: Cigarette smoking is a major risk factor for acute coronary thrombosis. In fact, both active/first-hand smoke and passive/second-hand smoke exposure are known to increase the risk of coronary thrombosis. Although recently a new risk has been identified and termed third-hand smoke (THS), which is the residual tobacco smoke contaminant that remains after a cigarette is extinguished, it remains to be determined whether it can also enhance the risk of thrombogenesis, much like first-hand smoke and second-hand smoke. Therefore, the present studies investigated the impact of THS exposure in the context of platelet biology and related disease states. It was found that THS-exposed mice exhibited an enhanced platelet aggregation and secretion responses as well as enhanced integrin GPIIb-IIIa activation. Furthermore, it was found that THS exposure shortens the tail bleeding time and the occlusion time in a model of thrombosis. Thus, our data demonstrate for the first time (at least in mice) that THS exposure increases the risk of thrombosis-based disease states, which is attributed, at least in part, to their hyperactive platelets.

*Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA; and

Department of Cell Biology and Neuroscience, University of California, Riverside, CA.

Reprints: Fadi T. Khasawneh, PhD, Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, 309 E. Second St, Pomona, CA 91766 (e-mail: fkhasawneh@westernu.edu).

Supported by funds from the College of Pharmacy, Western University of Health Sciences, Pomona, CA (F.T.K.), and the Tobacco-Related Disease Research Program (19XT-0166; M.M.-G.).

The authors report no conflicts of interest.

Received February 01, 2015

Accepted March 18, 2015

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.